Key Insights

Highlights

Success Rate

83% trial completion

Published Results

11 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

7.2%

5 terminated out of 69 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

12%

8 trials in Phase 3/4

Results Transparency

44%

11 of 25 completed with results

Key Signals

11 with results83% success

Data Visualizations

Phase Distribution

56Total
Not Applicable (18)
P 1 (4)
P 2 (26)
P 3 (4)
P 4 (4)

Trial Status

Completed25
Unknown15
Not Yet Recruiting9
Recruiting6
Active Not Recruiting6
Terminated5

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (69)

Showing 20 of 20 trials
NCT06653192Not ApplicableSuspended

EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)

NCT06375967Not ApplicableSuspended

EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)

NCT07532759Not ApplicableNot Yet Recruiting

Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

NCT01950572Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

NCT03406299Phase 2CompletedPrimary

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

NCT04910386Phase 2Not Yet RecruitingPrimary

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

NCT03875235Phase 3Active Not RecruitingPrimary

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT02829918Phase 2Completed

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

NCT07146646Phase 2Recruiting

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

NCT04579380Phase 2Active Not Recruiting

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT07269158Phase 1Not Yet RecruitingPrimary

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

NCT07252570CompletedPrimary

Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes

NCT04956640Phase 1Recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT05429203Not ApplicableCompleted

Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope

NCT07160283Phase 2Not Yet RecruitingPrimary

The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer

NCT07109167Phase 2Not Yet RecruitingPrimary

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

NCT03801083Phase 2Recruiting

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

NCT03478488Phase 3Active Not RecruitingPrimary

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

NCT00359320Not ApplicableTerminated

A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy

Scroll to load more

Research Network

Activity Timeline